Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

NANOMEDICINE FOR ORGAN TRANSPLANTATION TOLERANCE (PHOENIX)

Project description

Nanotechnology for transplant medicine

Organ transplant medicine currently requires lifelong immunosuppression, increasing the risk of infections, cancers, and cardiovascular diseases, with a 20 % rate of long-term graft failure. Recent advancements in peptide-MHC complex-based nanomedicines could transform the field by reprogramming the local immune environment around a transplanted organ, promoting long-term tolerance without systemic immunosuppression. The EU-funded PHOENIX project aims to develop and validate a nanotechnology platform for transplant medicine, drawing on expertise in murine kidney and liver transplant models, as well as liver transplantation in pigs. The project will design a nanomedicine that delivers common antigens to redirect the host immune response toward graft tolerance and regulation, demonstrating its efficacy in murine and porcine models.

Objective

PROBLEM: Today, organ transplant medicine is limited by life-long immunosuppression and vulnerability to infections, malignancies and cardiovascular diseases, and by a 20% rate of long-term graft failure.

SOLUTION: PHOENIX reprograms the local immune micro-environment around a graft organ, inducing long-term transplant tolerance without broader systemic immunosuppression.

FOUNDATIONS: Our expert teams have already discovered novel peptide-MHC complex-based nanomedicines for the treatment of autoimmune diseases. This project will transform, deploy and validate this nano-technology platform for transplant medicine. We have unique expertise in kidney and liver murine transplant models as well as liver transplantation in pigs and have established a molecular engineering pipeline for immune-protein synthesis to enable future clinical translation. Extensive clinical-trial expertise will enable us to progress efficiently from this project towards the clinic.

WORKPLAN: We are designing and building a unique nanomedicine which delivers ubiquitous or self-antigens - common to all humans – that will redirect the host immune response against the graft toward regulation and tolerance development. These medicines will be demonstrated in murine and porcine models, laying the foundation for human clinical trials immediately post-project.

SUMMARY: This project combines innovative multi-disciplinary approaches, building on a proven foundation, to deliver a novel therapy which will have a transformative positive effect on organ transplant patients and healthcare.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project's classification has been validated by the project's team.

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-HLTH-2022-DISEASE-06-two-stage

See all projects funded under this call

Coordinator

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 075 485,04
Address
VIA MARIO NEGRI 2
20156 MILANO
Italy

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 075 485,04

Participants (4)

My booklet 0 0